127 related articles for article (PubMed ID: 38692811)
1. Pathologic Response Evaluation in Neoadjuvant-Treated Lung Cancer.
Dacic S
Surg Pathol Clin; 2024 Jun; 17(2):287-293. PubMed ID: 38692811
[TBL] [Abstract][Full Text] [Related]
2. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
Weissferdt A; Leung CH; Lin H; Sepesi B; William WN; Swisher SG; Cascone T; Lee JJ; Pataer A
Mod Pathol; 2024 Jan; 37(1):100353. PubMed ID: 37844869
[TBL] [Abstract][Full Text] [Related]
3. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
Dacic S; Travis W; Redman M; Saqi A; Cooper WA; Borczuk A; Chung JH; Glass C; Lopez JM; Roden AC; Sholl L; Weissferdt A; Posadas J; Walker A; Zhu H; Wijeratne MT; Connolly C; Wynes M; Bota-Rabassedas N; Sanchez-Espiridion B; Lee JJ; Berezowska S; Chou TY; Kerr K; Nicholson A; Poleri C; Schalper KA; Tsao MS; Carbone DP; Ready N; Cascone T; Heymach J; Sepesi B; Shu C; Rizvi N; Sonett J; Altorki N; Provencio M; Bunn PA; Kris MG; Belani CP; Kelly K; Wistuba I;
J Thorac Oncol; 2023 Oct; 18(10):1290-1302. PubMed ID: 37702631
[TBL] [Abstract][Full Text] [Related]
4. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild SI; Zippelius A; Eboulet EI; Savic Prince S; Betticher D; Bettini A; Früh M; Joerger M; Lardinois D; Gelpke H; Mauti LA; Britschgi C; Weder W; Peters S; Mark M; Cathomas R; Ochsenbein AF; Janthur WD; Waibel C; Mach N; Froesch P; Buess M; Bohanes P; Godar G; Rusterholz C; Gonzalez M; Pless M;
J Clin Oncol; 2021 Sep; 39(26):2872-2880. PubMed ID: 34251873
[TBL] [Abstract][Full Text] [Related]
5. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
6. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
Cottrell TR; Thompson ED; Forde PM; Stein JE; Duffield AS; Anagnostou V; Rekhtman N; Anders RA; Cuda JD; Illei PB; Gabrielson E; Askin FB; Niknafs N; Smith KN; Velez MJ; Sauter JL; Isbell JM; Jones DR; Battafarano RJ; Yang SC; Danilova L; Wolchok JD; Topalian SL; Velculescu VE; Pardoll DM; Brahmer JR; Hellmann MD; Chaft JE; Cimino-Mathews A; Taube JM
Ann Oncol; 2018 Aug; 29(8):1853-1860. PubMed ID: 29982279
[TBL] [Abstract][Full Text] [Related]
7. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
[TBL] [Abstract][Full Text] [Related]
8. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
Travis WD; Dacic S; Wistuba I; Sholl L; Adusumilli P; Bubendorf L; Bunn P; Cascone T; Chaft J; Chen G; Chou TY; Cooper W; Erasmus JJ; Ferreira CG; Goo JM; Heymach J; Hirsch FR; Horinouchi H; Kerr K; Kris M; Jain D; Kim YT; Lopez-Rios F; Lu S; Mitsudomi T; Moreira A; Motoi N; Nicholson AG; Oliveira R; Papotti M; Pastorino U; Paz-Ares L; Pelosi G; Poleri C; Provencio M; Roden AC; Scagliotti G; Swisher SG; Thunnissen E; Tsao MS; Vansteenkiste J; Weder W; Yatabe Y
J Thorac Oncol; 2020 May; 15(5):709-740. PubMed ID: 32004713
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study.
Zhang Y; Fu F; Hu H; Wang S; Li Y; Hu H; Chen H
J Thorac Cardiovasc Surg; 2021 Feb; 161(2):434-442.e2. PubMed ID: 32340810
[TBL] [Abstract][Full Text] [Related]
10. Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.
Qu Y; Emoto K; Eguchi T; Aly RG; Zheng H; Chaft JE; Tan KS; Jones DR; Kris MG; Adusumilli PS; Travis WD
J Thorac Oncol; 2019 Mar; 14(3):482-493. PubMed ID: 30503889
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
Pataer A; Weissferdt A; Vaporciyan AA; Correa AM; Sepesi B; Wistuba II; Heymach JV; Cascone T; Swisher SG
J Thorac Oncol; 2021 Aug; 16(8):1289-1297. PubMed ID: 33857666
[TBL] [Abstract][Full Text] [Related]
12. [Pathological assessment of non-small cell lung cancer resection specimens after neoadjuvant therapy].
Huang Y; Zhang LP; Hou LK; Dong ZW; Zhang W; Wu W; Wu CY
Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):773-778. PubMed ID: 34405613
[No Abstract] [Full Text] [Related]
13. Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer.
Liu X; Sun W; Wu J; Feng Y; Mao L; Chen M; Yang X; Wang H; Chi K; Yang Y; Lin D
Mod Pathol; 2021 Nov; 34(11):1990-1998. PubMed ID: 34253867
[TBL] [Abstract][Full Text] [Related]
14. Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?
Cai JS; Li S; Yan SM; Yang J; Yang MZ; Xie CL; Li JB; Feng YF; Yang HX; Hou X
Thorac Cancer; 2021 May; 12(9):1336-1346. PubMed ID: 33751832
[TBL] [Abstract][Full Text] [Related]
15. Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.
Weissferdt A; Pataer A; Swisher SG; Heymach JV; Gibbons DL; Cascone T; Sepesi B
Lung Cancer; 2021 Apr; 154():76-83. PubMed ID: 33631448
[TBL] [Abstract][Full Text] [Related]
16. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
17. Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.
Dacic S; Travis WD; Giltnane JM; Kos F; Abel J; Hilz S; Fujimoto J; Sholl L; Ritter J; Khalil F; Liu Y; Taylor-Weiner A; Resnick M; Yu H; Hirsch FR; Bunn PA; Carbone DP; Rusch V; Kwiatkowski DJ; Johnson BE; Lee JM; Hennek SR; Wapinski I; Nicholas A; Johnson A; Schulze K; Kris MG; Wistuba II
J Thorac Oncol; 2024 May; 19(5):719-731. PubMed ID: 38070597
[TBL] [Abstract][Full Text] [Related]
18. Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study.
Ahmed S; Birnbaum AE; Safran HP; Dipetrillo TA; Aswad BI; Ready NE; Ng T
J Thorac Oncol; 2011 Aug; 6(8):1432-4. PubMed ID: 21847062
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy followed by surgery in lung cancer: Indian scenario.
Kumar S; Saikia J; Kumar V; Malik PS; Madan K; Jain D; Bharati S
Curr Probl Cancer; 2020 Jun; 44(3):100563. PubMed ID: 32265058
[TBL] [Abstract][Full Text] [Related]
20. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy.
Liu-Jarin X; Stoopler MB; Raftopoulos H; Ginsburg M; Gorenstein L; Borczuk AC
Mod Pathol; 2003 Nov; 16(11):1102-8. PubMed ID: 14614049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
